<DOC>
	<DOCNO>NCT02911857</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability ACZ885 extension study . This extension study offer opportunity patient complete Epoch 4 precede CACZ885N2301 study continue treat ACZ885 approval Japan drug Periodic Fever Syndromes development ACZ885 Periodic Fever Syndromes suspend .</brief_summary>
	<brief_title>An Extention Study Safety Canakinumab Japanese Patients With Periodic Fever Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Completed Epoch 4 CACZ885N2301 study Japan approval canakinumab Japan Written inform consent . Parent legal guardian 's write informed consent child 's assent , appropriate , required assessment perform patient &lt; 20 year age Any condition significant medical problem investigator judge patient enter extension study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Canakinumab</keyword>
	<keyword>TRAPS</keyword>
	<keyword>extension study</keyword>
	<keyword>interleukin-1</keyword>
	<keyword>Periodic Fevers Syndrome</keyword>
	<keyword>HIDS</keyword>
	<keyword>crFMF</keyword>
	<keyword>auto-inflammatory disease</keyword>
</DOC>